- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different": AmerisourceBergen's Sean McGowan Takes a Closer Look at US Biosimilar Launches
With us on the podcast to talk about recent and upcoming biosimilar launches is Sean McGowan, senior director of biosimilars at AmerisourceBergen. McGowen spoke with us about what the US biosimilars market needs now in order to thrive and tells us which developments he’ll be watching closely in 2020.
For stakeholders in the US biosimilars market, the past few months have been exciting times. We’ve seen multiple product approvals, and the launch of a number of highly anticipated and long-awaited biosimilar products. With us on the podcast today to talk about these developments is Sean McGowan, senior director of biosimilars at AmerisourceBergen.
McGowan is responsible for leading strategy and business development initiatives for the biosimilar product category, and partners with biosimilar manufacturers in the precommercial, launch, and postlaunch phases. He also leads internal collaboration with customer groups to guarantee open access to biosimilars. McGowen spoke with us about the recent biosimilar launches in the United States, what the US biosimilars market needs now in order to thrive, and developments ahead in 2020.
Read more about the upcoming launches of multiple biosimilars from Pfizer, about Truxima, about Ziextenzo, and about Ogivri.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilars Policy Roundup for March 2023—Podcast Edition
August 4th 2025On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
August 4th 2025On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
